Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 73, No 5 (2022)
Review paper
Submitted: 2021-10-05
Accepted: 2022-01-18
Published online: 2022-08-12
View PDF Download PDF file View HTML
Get Citation

Lipid profile abnormalities associated with endocrine disorders

Ewelina Szczepanek-Parulska1, Jan Sokolowski1, Dominika Dmowska1, Jan Klimek1, Tomasz Stasikowski1, Paweł Zdebski1, Michal Olejarz1, Anna Gac1, Michał Bartecki2, Marek Ruchała1
DOI: 10.5603/EP.a2022.0059
·
Pubmed: 35971925
·
Endokrynol Pol 2022;73(5):863-871.
Affiliations
  1. Department of Endocrinology, Metabolism, and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Paediatric Cardiology, University of Medical Sciences, Poznan, Poland

open access

Vol 73, No 5 (2022)
Review Article
Submitted: 2021-10-05
Accepted: 2022-01-18
Published online: 2022-08-12

Abstract

Nearly 30% of patients with lipid profile abnormalities suffer from secondary dyslipidaemias. Endocrine disorders are one of the most important causes of dyslipidaemia. Dyslipidaemia can be observed in the pathologies of a variety of endocrine glands, including the thyroid, the pituitary, the adrenals, and the gonads. The most common endocrinopathy causing dyslipidaemia is hypothyroidism.

In this paper, we review the lipid profile alterations observed in endocrinopathies. We describe changes in classic lipid profile parameters, including total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. However, we also focus on the influence of endocrine disorders on relatively new cardiovascular markers such as apolipoprotein B, apolipoprotein A1, and lipoprotein(a). While almost all endocrinopathies cause detrimental changes to the lipid profile, hyperthyroidism seems to be a disorder in which lowering of such parameters as total cholesterol, low-density cholesterol, and triglycerides can be observed. Comprehensive screening for endocrine disorders should always be included in the differential diagnostic process of secondary causes of dyslipidaemia.

Early detection and treatment of endocrinopathy have a considerable impact on a patient’s health. Proper treatment of those disorders plays a crucial role in modifying the cardiovascular risk and improving the lipid profile of those patients. Even though lipid-lowering therapy is usually still needed, in some cases restoration of hormonal balance might be sufficient to normalize the lipid profile abnormalities.

Abstract

Nearly 30% of patients with lipid profile abnormalities suffer from secondary dyslipidaemias. Endocrine disorders are one of the most important causes of dyslipidaemia. Dyslipidaemia can be observed in the pathologies of a variety of endocrine glands, including the thyroid, the pituitary, the adrenals, and the gonads. The most common endocrinopathy causing dyslipidaemia is hypothyroidism.

In this paper, we review the lipid profile alterations observed in endocrinopathies. We describe changes in classic lipid profile parameters, including total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. However, we also focus on the influence of endocrine disorders on relatively new cardiovascular markers such as apolipoprotein B, apolipoprotein A1, and lipoprotein(a). While almost all endocrinopathies cause detrimental changes to the lipid profile, hyperthyroidism seems to be a disorder in which lowering of such parameters as total cholesterol, low-density cholesterol, and triglycerides can be observed. Comprehensive screening for endocrine disorders should always be included in the differential diagnostic process of secondary causes of dyslipidaemia.

Early detection and treatment of endocrinopathy have a considerable impact on a patient’s health. Proper treatment of those disorders plays a crucial role in modifying the cardiovascular risk and improving the lipid profile of those patients. Even though lipid-lowering therapy is usually still needed, in some cases restoration of hormonal balance might be sufficient to normalize the lipid profile abnormalities.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

dyslipidaemia; endocrine diseases; hyperthyroidism; hypothyroidism, acromegaly; Cushing’s disease

About this article
Title

Lipid profile abnormalities associated with endocrine disorders

Journal

Endokrynologia Polska

Issue

Vol 73, No 5 (2022)

Article type

Review paper

Pages

863-871

Published online

2022-08-12

Page views

4374

Article views/downloads

738

DOI

10.5603/EP.a2022.0059

Pubmed

35971925

Bibliographic record

Endokrynol Pol 2022;73(5):863-871.

Keywords

dyslipidaemia
endocrine diseases
hyperthyroidism
hypothyroidism
acromegaly
Cushing’s disease

Authors

Ewelina Szczepanek-Parulska
Jan Sokolowski
Dominika Dmowska
Jan Klimek
Tomasz Stasikowski
Paweł Zdebski
Michal Olejarz
Anna Gac
Michał Bartecki
Marek Ruchała

References (96)
  1. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012; 110(6): 823–825.
    CrossRefPubMed
  2. Bułdak Ł, Marek B, Kajdaniuk D, et al. Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol Pol. 2019; 70(6): 511–519.
    CrossRefPubMed
  3. Devaraj S, Semaan JR, Jialal I. Biochemistry. Apolipoprotein B. StatPearls, Treasure Island 2021.
  4. Nakajima K, Nagamine T, Fujita MQ, et al. Apolipoprotein B-48: a unique marker of chylomicron metabolism. Adv Clin Chem. 2014; 64: 117–177.
    PubMed
  5. Contois JH, McConnell JP, Sethi AA, et al. AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009; 55(3): 407–419.
    CrossRefPubMed
  6. Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012; 4(4): 251–268.
    CrossRefPubMed
  7. Chistiakov DA, Orekhov AN, Bobryshev YV. ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease. Lab Invest. 2016; 96(7): 708–718.
    CrossRefPubMed
  8. McCormick SPA. Lipoprotein(a): biology and clinical importance. Clin Biochem Rev. 2004; 25(1): 69–80.
    PubMed
  9. Vanderpump M. The epidemiology of thyroid disease. Br Med Bull. 2011; 99(1): 39–51.
    CrossRefPubMed
  10. Aoki Y, Belin RM, Clickner R, et al. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid. 2007; 17(12): 1211–1223.
    CrossRefPubMed
  11. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, et al. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014; 99(3): 923–931.
    CrossRefPubMed
  12. Asvold BO, Vatten LJ, Nilsen TIL, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007; 156(2): 181–186.
    CrossRefPubMed
  13. Goldberg IJ, Huang LS, Huggins LA, et al. Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. Endocrinology. 2012; 153(11): 5143–5149.
    CrossRefPubMed
  14. O'Brien T, Katz K, Hodge D, et al. The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E. Clin Endocrinol (Oxf). 1997; 46(1): 17–20.
    CrossRefPubMed
  15. Kaliaperumal R, William E, Selvam T, et al. Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients. J Clin Diagn Res. 2014; 8(2): 37–39.
    CrossRefPubMed
  16. Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J. 2011; 5: 76–84.
    CrossRefPubMed
  17. Mugii S, Hanada H, Okubo M, et al. Thyroid function influences serum apolipoprotein B-48 levels in patients with thyroid disease. J Atheroscler Thromb. 2012; 19(10): 890–896.
    CrossRefPubMed
  18. Ito M, Kitanaka A, Arishima T, et al. Effect of L-thyroxine replacement on apolipoprotein B-48 in overt and subclinical hypothyroid patients. Endocr J. 2013; 60(1): 65–71.
    CrossRefPubMed
  19. Becerra A, Bellido D, Luengo A, et al. Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy. Clin Nutr. 1999; 18(5): 319–322.
    CrossRefPubMed
  20. Murase T, Arimoto S, Okubo M, et al. Significant reduction of elevated serum lipoprotein(a) concentrations during levo-thyroxine-replacement therapy in a hypothyroid patient. J Clin Lipidol. 2012; 6(4): 388–391.
    CrossRefPubMed
  21. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2): 489–499.
    CrossRefPubMed
  22. Tzotzas T, Krassas GE, Konstantinidis T, et al. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid. 2000; 10(9): 803–808.
    CrossRefPubMed
  23. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab. 2002; 87(4): 1533–1538.
    CrossRefPubMed
  24. Toruner F, Altinova AE, Karakoc A, et al. Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. Adv Ther. 2008; 25(5): 430–437.
    CrossRefPubMed
  25. Villar H, Saconato H, Valente O, et al. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev. 2001.
    CrossRef
  26. Cojić M, Cvejanov-Kezunović L. Subclinical Hypothyroidism - Whether and When To Start Treatment? Open Access Maced J Med Sci. 2017; 5(7): 1042–1046.
    CrossRefPubMed
  27. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018; 14(5): 301–316.
    CrossRefPubMed
  28. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10): 1343–1421.
    CrossRefPubMed
  29. Peppa M, Betsi G, Dimitriadis G. Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease. J Lipids. 2011; 2011: 575840.
    CrossRefPubMed
  30. Kotwal A, Cortes T, Genere N, et al. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2020; 105(12).
    CrossRefPubMed
  31. Liberopoulos E, Miltiadous G, Elisaf M. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism. Diabetes Obes Metab. 2001; 3(2): 97–98.
    CrossRefPubMed
  32. Andrikoula M, Avades T. Hypolipidaemia is not always indicating liver dysfunction. A review of primary and secondary high density lipoprotein and low density lipoprotein deficiencies. Minerva Med. 2006; 97: 487–494.
    PubMed
  33. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000; 80(4): 1523–1631.
    CrossRefPubMed
  34. Ling C, Svensson L, Odén B, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003; 88(4): 1804–1808.
    CrossRefPubMed
  35. Jiang XB, He DS, Mao ZG, et al. BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort. Tumour Biol. 2013; 34(2): 1171–1176.
    CrossRefPubMed
  36. Toulis KA, Robbins T, Reddy N, et al. Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol (Oxf). 2018; 88(1): 71–76.
    CrossRefPubMed
  37. Krysiak R, Marek B, Okopień B. Cardiometabolic risk factors in young women with macroprolactinaemia. Endokrynol Pol. 2019; 70(4): 336–341.
    CrossRefPubMed
  38. Berinder K, Nyström T, Höybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011; 14(3): 199–207.
    CrossRefPubMed
  39. Ruchała M, Szczepanek-Parulska E, Fularz M, et al. Risk of neoplasms in acromegaly. Contemp Oncol (Pozn). 2012; 16(2): 111–117.
    CrossRefPubMed
  40. Bolanowski M, Ruchała M, Zgliczyński W, et al. Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. Endokrynol Pol. 2019; 70(1): 2–18.
    CrossRefPubMed
  41. Qiu H, Yang JK, Chen C. Influence of insulin on growth hormone secretion, level and growth hormone signalling. Sheng Li Xue Bao. 2017; 69(5): 541–556.
    PubMed
  42. Szczepańiska Kostro J, Tołwińska J, Urban M, et al. Cardiac mass and function, carotid artery intima media thickness, homocysteine and lipoprotein levels in children and adolescents with growth hormone deficiency. J Pediatr Endocrinol Metab. 2004; 17(10): 1405–1413.
    PubMed
  43. Cummings MH, Christ E, Umpleby AM, et al. Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency. J Clin Endocrinol Metab. 1997; 82(6): 2010–2013.
    PubMed
  44. Giovannini L, Tirabassi G, Muscogiuri G, et al. Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J. 2015; 62(12): 1037–1048.
    CrossRefPubMed
  45. Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986; 314(8): 488–500.
    CrossRefPubMed
  46. Rosén T, Edén S, Larson G, et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993; 129(3): 195–200.
    CrossRefPubMed
  47. van der Klaauw AA, Biermasz NR, Feskens EJM, et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol. 2007; 156(4): 455–462.
    CrossRefPubMed
  48. Kohno H, Tanaka T, Fujieda K, et al. Favorable Impacts of Growth Hormone (GH) Replacement Therapy on Atherogenic Risks in Japanese Children with GH Deficiency. Clin Pediatr Endocrinol. 2012; 21(2): 15–20.
    CrossRefPubMed
  49. Norrman LL, Johannsson G, Sunnerhagen KS, et al. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab. 2008; 93(7): 2531–2538.
    CrossRefPubMed
  50. Edén S, Wiklund O, Oscarsson J, et al. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb. 1993; 13(2): 296–301.
    CrossRefPubMed
  51. Elbornsson M, Götherström G, Bosæus I, et al. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013; 168(5): 745–753.
    CrossRefPubMed
  52. Boot AM, Engels MA, Boerma GJ, et al. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J Clin Endocrinol Metab. 1997; 82(8): 2423–2428.
    CrossRefPubMed
  53. Foster C, Burton A, Scholl J, et al. Lipid patterns in treated growth hormone deficient children vs. short stature controls. J Pediatr Endocrinol Metab. 2014; 27(9-10): 909–914.
    CrossRefPubMed
  54. Mercado M, Ramírez-Rentería C. Metabolic Complications of Acromegaly. Front Horm Res. 2018; 49: 20–28.
    CrossRefPubMed
  55. Feingold KR, Brinton EA, Grunfeld C. The Effect of Endocrine Disorders on Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A. et al. ed. Endotext. South Dartmouth 2000.
  56. Wang M, Guo S, He M, et al. High-Performance Liquid Chromatography-Mass Spectrometry-Based Lipid Metabolite Profiling of Acromegaly. J Clin Endocrinol Metab. 2020; 105(3).
    CrossRefPubMed
  57. Takeda R, Tatami R, Ueda K, et al. Secondary type V hyperlipoproteinemia in an acromegalic patient without overt diabetes. Endokrinologie. 1982; 79: 140–148.
  58. Beentjes JA, van Tol A, Sluiter WJ, et al. Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis. 2000; 153(2): 491–498.
    CrossRefPubMed
  59. Cansu GB, Yılmaz N, Yanıkoğlu A, et al. ssessment of Diastolic Dysfunction, Arterial Stiffness, and Carotid Intima-Media Thickness in Patients with Acromegaly. Endocr Pract. 2017; 23(5): 536–545.
    CrossRefPubMed
  60. Arosio M, Sartore G, Rossi CM, et al. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis. 2000; 151(2): 551–557.
    CrossRefPubMed
  61. Caron PJ, Petersenn S, Houchard A, et al. PRIMARYS Study Group. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf). 2017; 86(4): 541–551.
    CrossRefPubMed
  62. Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009; 94(8): 2692–2701.
    CrossRefPubMed
  63. Arnaldi G, Scandali VM, Trementino L, et al. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010; 92 Suppl 1: 86–90.
    CrossRefPubMed
  64. Mancini T, Kola B, Mantero F, et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf). 2004; 61(6): 768–777.
    CrossRefPubMed
  65. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab. 1999; 84(8): 2664–2672.
    CrossRefPubMed
  66. Szczepanek-Parulska E, Cyranska-Chyrek E, Nowaczyk M, et al. Diagnostic Difficulties In a Young Women With Symptoms of Cushing Syndrome. Endocr Pract. 2018; 24(8): 766.
    CrossRefPubMed
  67. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003; 88(6): 2527–2533.
    CrossRefPubMed
  68. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A. (eds). ed. Endotext. South Dartmouth, 2000 .
  69. Haring R, Baumeister SE, Völzke H, et al. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil. 2011; 18(1): 86–96.
    CrossRefPubMed
  70. Muraleedharan V, Jones TH. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab. 2010; 1(5): 207–223.
    CrossRefPubMed
  71. Gagliano-Jucá T, Basaria S. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. 2019; 16(9): 555–574.
    CrossRefPubMed
  72. Mohler ER, Ellenberg SS, Lewis CE, et al. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. J Clin Endocrinol Metab. 2018; 103(2): 681–688.
    CrossRefPubMed
  73. Kaplan SA, Lin J, Johnson-Levonas AO, et al. Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone. Aging Male. 2010; 13(1): 40–43.
    CrossRefPubMed
  74. Zhang J, Yang B, Xiao W, et al. Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review. World J Urol. 2018; 36(8): 1315–1326.
    CrossRefPubMed
  75. Thirumalai A, Rubinow KB, Page ST. An update on testosterone, HDL and cardiovascular risk in men. Clin Lipidol. 2015; 10(3): 251–258.
    CrossRefPubMed
  76. Zhang KS, Zhao MJ, An Q, et al. Effects of testosterone supplementation therapy on lipid metabolism in hypogonadal men with T2DM: a meta-analysis of randomized controlled trials. Andrology. 2018; 6(1): 37–46.
    CrossRefPubMed
  77. Gaeta G, Lanero S, Barra S, et al. Sex hormones and lipoprotein(a) concentration. Expert Opin Investig Drugs. 2011; 20(2): 221–238.
    CrossRefPubMed
  78. Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab. 2011; 96(4): 885–893.
    CrossRefPubMed
  79. Schaefer EJ, Lamon-Fava S, Johnson S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993; 87(4): 1135–1141.
    CrossRefPubMed
  80. Anagnostis P, Stevenson JC, Crook D, et al. Effects of gender, age and menopausal status on serum apolipoprotein concentrations. Clin Endocrinol (Oxf). 2016; 85(5): 733–740.
    CrossRefPubMed
  81. Anagnostis P, Karras S, Lambrinoudaki I, et al. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. Int J Clin Pract. 2016; 70(12): 967–977.
    CrossRefPubMed
  82. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol. 2002; 90(8A): 77i–84i.
    CrossRefPubMed
  83. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993; 87(4): 1135–1141.
    CrossRefPubMed
  84. Lip GY, Blann AD, Jones AF, et al. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J. 1997; 134(4): 764–771.
    CrossRefPubMed
  85. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril. 2001; 75(5): 898–915.
    CrossRefPubMed
  86. Lobo RA. Clinical review 27: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991; 73(5): 925–930.
    CrossRefPubMed
  87. Marlatt KL, Lovre D, Beyl RA, et al. Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women. Eur J Endocrinol. 2020; 183(4): 439–452.
    CrossRefPubMed
  88. Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019; 26(9): 1071–1084.
    CrossRefPubMed
  89. Dutkowska A, Konieczna A, Breska-Kruszewska J, et al. [Recomendations on non-pharmacological interventions in women with PCOS to reduce body weight and improve metabolic disorders [Zalecenia dotyczące postępowania niefarmakologicznego u kobiet z PCOS celem zmniejszenia masy ciała i poprawy zaburzeń metabolicznych]]. Endokrynol Pol. 2019; 70(2): 198–212.
    CrossRefPubMed
  90. Kim JJu, Hwang KRi, Choi YM, et al. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Hum Reprod. 2013; 28(5): 1354–1360.
    CrossRefPubMed
  91. Wild RA. Dyslipidemia in PCOS. Steroids. 2012; 77(4): 295–299.
    CrossRefPubMed
  92. Vine DF, Wang Ye, Jetha MM, et al. Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017; 102(3): 970–982.
    CrossRefPubMed
  93. Kałużna M, Człapka-Matyasik M, Wachowiak-Ochmańska K, et al. Effect of Central Obesity and Hyperandrogenism on Selected Inflammatory Markers in Patients with PCOS: A WHtR-Matched Case-Control Study. J Clin Med. 2020; 9(9).
    CrossRefPubMed
  94. Kałużna M, Krauze T, Ziemnicka K, et al. Cardiovascular, anthropometric, metabolic and hormonal profiling of normotensive women with polycystic ovary syndrome with and without biochemical hyperandrogenism. Endocrine. 2021; 72(3): 882–892.
    CrossRefPubMed
  95. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014; 171(4): P1–P29.
    CrossRefPubMed
  96. Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013; 98(12): 4798–4807.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl